**Name of journal:** ***World Journal of Gastroenterology***

**Manuscript NO: 37520**

**Manuscript type: CASE REPORT**

**Detection of fusion gene in cell-free DNA of a gastric synovial sarcoma**

Ogino S *et al.* Liquid biopsy monitoring of synovial sarcoma

Shinpei Ogino, Hirotaka Konishi, Daisuke Ichikawa, Junichi Hamada, Katsutoshi Shoda, Tomohiro Arita, Shuhei Komatsu, Atsushi Shiozaki, Kazuma Okamoto, Sanae Yamazaki, Satoru Yasukawa, Eiichi Konishi, Eigo Otsuji

**Shinpei Ogino, Hirotaka Konishi, Daisuke Ichikawa, Junichi Hamada, Katsutoshi Shoda, Tomohiro Arita, Shuhei Komatsu, Atsushi Shiozaki, Kazuma Okamoto, Eigo Otsuji**, Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan

**Sanae Yamazaki, Satoru Yasukawa, Eiichi Konishi**, Department of Surgical Pathology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto 602-8566, Japan

**ORCID number:** Shinpei Ogino(0000-0001-9867-7623); Hirotaka Konishi (0000-0002-4899-8944); Daisuke Ichikawa (0000-0003-0093-2206); Katsutoshi Shoda (0000-0002-1011-5579); Tomohiro Arita (0000-0001-7127-6504); Shuhei Komatsu (0000-0001-6074-7614); Atsushi Shiozaki (0000-0003-3739-160X); Kazuma Okamoto (0000-0002-8270-4217); Eiichi Konishi (0000-0002-1194-1186); Eigo Otsuji (0000-0002-3260-8155).

**Author contributions:** Ogino S, Konishi H and Otsuji E analyzed the patient data and were major contributor in writing the manuscript; Ichikawa D, Hamada J, Shoda K, Arita T, Komatsu S, Shiozaki A and Okamoto K performed patient treatment and sample collections; Yamazaki S, Yasukawa S and Konishi E performed the pathological diagnosis; all authors read and approved the final manuscript.

**Informed consent statement:** The study participant provided informed written consent prior to their treatments and study enrollment.

**Conflict-of-interest statement:** All authors declare no conflict of interest related to this study or its publication.

**CARE Checklist (2013) statement:** The authors have read the CARE Checklist (2013), and the manuscript was prepared and revised according to the CARE Checklist (2013).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Hirotaka Konishi, MD, PhD,** Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. h-koni7@koto.kpu-m.ac.jp

**Telephone:** +81-75-2515527

**Fax:** +81-75-2515522

**Received:** December 14, 2017

**Peer-review started:** December 14, 2017

**First decision:** January 5, 2018

**Revised:** January 11, 2018

**Accepted:** January 20, 2018

**Article in press:**

**Published online:**

**Abstract**

Synovial sarcoma (SS) is genetically characterized by chromosomal translocation, which generates *SYT-SSX* fusion transcripts. Although SS can occur in any body part, primary gastric SS is substantially rare. Here we describe a detection of the fusion gene sequence of gastric SS in plasma cell-free DNA (cfDNA). A gastric submucosal tumor was detected in the stomach of a 27-year-old woman and diagnosed as SS. Candidate intronic primers were designed to detect the intronic fusion breakpoint and this fusion sequence was confirmed in intron 10 of *SYT* and intron 5 of *SSX2* by genomic polymerase chain reaction (PCR) and direct sequencing. A locked nucleic acid (LNA) probe specific to the fusion sequence was designed for detecting the fusion sequence in plasma and the fusion sequence was detected in preoperative plasma cfDNA, while not detected in postoperative plasma cfDNA. This technique will be useful for monitoring translocation-derived diseases such as SS.

**Key words:** Fusion gene; Gastric synovial sarcoma; Plasma; Cell free DNA

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Synovial sarcoma (SS) is genetically characterized by *SYT-SSX* fusion transcripts and detection of the fusion gene is necessary for a definitive diagnosis. This study demonstrated the detection of fusion sequence using cfDNA sample. A small gastric SS was detected in the stomach of a 27-year-old woman. Candidate intronic primers were designed and the intronic breakpoint was confirmed by PCR and direct sequencing in frozen tumor sample. A probe specific for fusion sequence was designed and the sequence was detected in preoperative cfDNA and frozen tumor sample. This technique will be useful for monitoring translocation-derived diseases such as SS.

Ogino S, Konishi H, Ichikawa D, Hamada J, Shoda K, Arita T, Komatsu S, Shiozaki A, Okamoto K, Yamazaki S, Yasukawa S, Konishi E, Otsuji E. Detection of fusion gene in cell-free DNA of a gastric synovial sarcoma. *World J Gastroenterol* 2018; In press

**Introduction**

Synovial sarcoma (SS), an aggressive soft tissue tumor, accounts for 7% of human soft tissue sarcomas[1]. Although SS frequently arises in large joint capsules in the extremities of young adults, it can occur in any body part, including the digestive tract. SS morphology resembles the developing synovial tissue; however, its origin remains unknown.

SS is genetically characterized by the reciprocal chromosomal translocation between X and 18 t (X; 18) (p11.2; q11.2) chromosomes, which generates *SYT-SSX* fusion transcripts[2,3]. *SYT* (GenBank accession number NC\_000018) is normally expressed in human tissues[4], whereas *SSX* expression is limited to normal testis and thyroid, and some variants are found in human malignancies[4-7]. The *SSX* family reportedly comprises nine highly homologous synovial sarcoma X genes (*SSX1–9*)[5]; however, *SSX1* or *SSX2* (GenBank accession number (SSX1) or NC\_000023) account for > 90% of t (X;18) translocations and *SSX4* is involved in few cases[7,8]. The breakpoints are frequently found within intron 10 of the *SYT* gene and intron 5 of the *SSX* gene[6-8]. The detection of the *SYT-SSX* fusion gene generally leads to SS diagnosis.

In this time, we could preoperatively diagnose with a primary gastric SS patient by reverse transcription polymerase chain reaction (RT-PCR)of biopsy tissue samples. Although some primary gastric SS cases have been reported, their preoperative diagnosis is rare. Its diagnosis is difficult solely on the basis of clinical or pathological findings[9-11]. Circulating nucleic acids were recently found to reflect the occurrence of cancer or monitoring of many diseases.Regarding SS, the production of the fusion gene *SYT-SSX* is a highly disease-specific alteration, and detecting the fusion gene in the patient’s circulation will represent a less-invasive diagnostic tool for this disease.

In this study, we report a detection of the fusion gene sequence in plasma circulating cfDNA.

**CASE REPORT**

***Materials and methods***

**Case of primary gastric SS:** A gastric ulcerated submucosal tumor was detected in the lower stomach of a 27-year-old woman using upper gastrointestinal endoscopy. Endoscopic ultrasound-guided biopsy was performed, and a spindle cell sarcoma compatible with SS was found in biopsy samples. The *SYT-SSX2* fusion gene was detected in tissue RNA of biopsy samples using RT-PCR. Laparoscopic gastrectomy was performed, and the tumor up to 20 mm diameter was pathologically diagnosed with SS. This patient remained disease free during the 6 mo follow-up.

The patient provided informed written consent for specimen collections and biomarker analyses, and the research was conducted with the approval of the ethics committees of the local institution and according to the Helsinki declaration.

**Tissue sample collections and tissue DNA and RNA extractions:** Tumor tissues and adjacent normal gastric tissues were obtained from operatively resected specimens and stored at -80 °C before DNA and RNA extractions. Total DNA and RNA were extracted from frozen samples using the AllPrep® DNA/RNA/miRNA universal kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Tissue RNA concentration was determined using a NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, United States), and the tissue DNA concentration was determined using a Qubit 3.0 fluorometer (Thermo Fisher Scientific).

**Plasma sample collections and plasma DNA extractions:** Seven-milliliter EDTA blood samples were obtained from the patient at three different times: before operation, 1 mo after the operation, and 6 mo after the operation. Blood samples were also obtained from 10 healthy volunteers. The plasma samples were instantly separated from the cellular fraction using a three-spin protocol (1500 rpm for 30 min, 3000 rpm for 5 min, and 4500 rpm for 5 min) and stored at -80 °C.

Circulating cell-free DNA (cfDNA) was isolated from 2 mL of each plasma sample using the QIAamp Circulating Nucleic Acid kit (Qiagen) according to the manufacturer’s instructions, and the cfDNA concentration was determined using the Qubit 3.0 fluorometer.

**Protocols for RT-PCR and genomic PCR of tissue samples:** Reverse transcribed reactions were performed with 400 ng tissue RNA in a 20 µL reaction volume using the high-capacity cDNA reverse transcription kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. The complementary DNA was subjected to PCR using AmpliTaq DNA polymerase (Thermo Fisher) and our designed primers (Table 1) with the following conditions: 10 min at 95 °C, followed by repetitions of 1 min at 95 °C, 1 min at 60 °C, and 30 s at 72 °C and a final extension step of 30 s at 72 °C.

Genomic PCR was performed with 10 ng genomic DNA (gDNA) in a 25 µL reaction volume using 1 unit of AmpliTaq DNA polymerase and 0.2 µmol/L of each primer (Table 1). PCR was run using the GeneAmp PCR System 9700 (Thermo Fisher) at the following conditions: 10 min at 95 °C, followed by repetitions of 1 min at 95 °C, 1 min at 53 °C (40 cycles), and 1 min at 72 °C and a final extension step of 30 s at 72 °C. The accurate length of the PCR products was confirmed using agarose gel electrophoresis. The images were obtained using the BLooK LED transilluminator (BIO-HELIX, Keelung, Taiwan) and a digital camera.

**Direct sequencing analysis:** The PCR products obtained were subjected to direct sequencing using the BigDye Terminator version1.1 Cycle Sequencing Kit (Thermo Fisher). Samples were run on ABI 3500 genetic analyzer (Applied Biosystems, Foster, United States).

**Detection of SYT-SSX2 fusion gene sequence:** To detect the fusion gene sequence in tissue and plasma samples, real-time PCR (RT-PCR) was performed in duplicates with 10 ng tissue DNA or 0.5 ng plasma cfDNA using the StepOne real-time PCR systems (Thermo Fisher). A pair of primers and specific probes using locked nucleic acid (LNA) bases for detecting the *SYT-SSX2* fusion gene sequence were designed (Table 1; Integrated DNA Technologies, Coralville, United States). The whole RT-PCR mixture (10 µL reaction volume) comprised DNA, Taqman Fast Advanced Master Mix (Thermo Fisher), RNase-free water, 0.5 µmol/L of each primer, and 0.25 µmol/L of probe solution and was performed with the following conditions: 2 min at 50 °C and 20 s at 95 °C, followed by repetitions of 1 s at 95 °C and 20 s at 60 °C (40 cycles).

**Statistical analysis:** BLAST software (<http://www.ncbi.nlm.nih.gov/BLAST/>) was used for sequence data analysis. The detection levels of the fusion gene sequence were compared with those obtained using the ΔΔCt method.

***Results***

**Confirmation of *SYT-SSX2* fusion gene occurrence in tumor tissues:** To confirm the fusion of the *SYT* and *SSX2* genes, RT-PCR was performed using total RNA extracted from tumor and adjacent normal tissues. The primer set was designed in exon 10 of the *SYT* gene (SYT-sense) and in exon 6 of the *SSX2* gene (SSX2-antisense) (Figure 1A) for an expected PCR product size of 118 base pairs. The sequence data of this primer sets are shown in Table 1. A PCR product of > 100 base pairs was obtained in tumor tissues only (Figure 1B), and direct sequencing of this PCR product confirmed the fusion between exon 10 of the *SYT* gene and exon 6 of the *SSX2* gene (Figure 1A and C).

**Detection of the genomic breakpoint:** To detect a genomic breakpoint in intron 10 of the *SYT* gene and intron 5 of the *SSX2* gene, 12 forward primers in *SYT* intron 10 and 3 reverse primers in *SSX2* intron 5 were designed at intervals of approximately 1000 base pairs (Figure 2A and Table 1). Genomic PCR was performed with each forward and reverse primer using gDNA extracted from tumor and normal tissues. The smallest PCR product, approximately 500 base pairs, was detected with the combination of SYT-8 and SSX2-4 primers in tumor tissues only (Figure 2B). The direct sequencing of the obtained PCR product showed a genomic breakpoint within the *SYT* and *SSX2* introns (Figure 2C).

**Production of the breakpoint-specific probe:** A breakpoint-specific FAM-labeled LNA probe and primer sets for RT-PCR analysis were designed to detect the *SYT-SSX2* fusion sequence in DNA samples (Figure 3A and B, Table 1). Using this specific probe and primer sets, the *SYT-SSX2* fusion sequence was detected in 10 ng of gDNA extracted from tumor tissues (Ct value; 31.6) (Table 2). Serial dilutions of gDNA extracted from tumor tissue were analyzed by RT-PCR using this specific probe and primer sets to confirm the accurate measurable range. The *SYT-SSX2* fusion sequence was detected proportional to gDNA concentrations from 1 to 0.063 ng (range of Ct value, up to 37, R2 = 0.974, *P* = 0.0018) (Figure 4A).

**Detection of the *SYT-SSX2* fusion sequence in cfDNA:** cfDNA extracted from the plasma was verified by RT-PCR using the specific probe and primer sets. The fusion sequence was detected in the plasma sample collected preoperatively from the patient but not in the plasma sample collected one or six months postoperatively from the patient or in the plasma samples of 10 healthy volunteers (Figure 4B). The Ct value was 35.9 in cfDNA collected preoperatively, whereas it was undetermined in other cfDNA (Not detected till 40 cycles) (Figure 4B).

**Discussion**

Primary gastric SS is a rare disease, and its diagnosis by clinical or pathological findings is difficult. Detection of the *SYT-SSX* fusion gene using a molecular biological approach is necessary for a definitive diagnosis. In most cases, this fusion gene or fusion sequence was identified from total RNA or DNA of tumor tissues by PCR method. Many alterations, such as microsatellite alteration[12], DNA methylation[13], and some mutations[14], in cancer cells have been recently detected in circulating cfDNA. Regarding translocation-derived diseases such as SS, it may also be possible to detect the fusion sequence in cfDNA. Indeed, Hayashi et al. reported that the *EWS-ETS* fusion gene, specific to Ewing sarcoma, was detected in circulating cfDNA extracted from plasma of a patient with Ewing sarcoma using long-range PCR and digital droplet PCR (ddPCR)[15].

In this study, we developed a highly specific locked nucleic acid (LNA) probe and primer sets for the *SYT-SSX2* fusion gene sequence and detected the sequence in cfDNA extracted from the plasma of a primary gastric SS patient. The translocation causes gene rearrangements in tumor tissues only; therefore, this probe and primer sets specific to the fusion sequence are highly unique to identify the intronic breakpoint. Moreover, the normal PCR method instead of highly accurate and sensitive methods such as ddPCR could detect the objective sequence in a small amount of cfDNA.

Nested PCR[8] or long-range PCR[15] techniques were previously reported for identifying the intronic fusion sequences of translation-related diseases. While the detection of *SYT-SSX* fusions in tumor tissues has been previously reported, this is the first report regarding the detection of the fusion sequence in circulating cfDNA. Since the discovery of circulating tumor cfDNA in 1994[16,17],investigations on cfDNA molecules have been proven to be useful for diagnosing or monitoring of disease states[11,18-21]. In this study, the fusion sequence could be detected in preoperative circulating cfDNA only, although the primary lesion was only 20 mm in diameter and undetectable by preoperative computed tomography. We expect the detection method of the *SYT-SSX* fusion sequence in circulating cfDNA to become an effective monitoring tool for SS, because > 90% of SS patients have this reciprocal translocation.

Numerous gene alterations have been recently identified using advanced technologies such as next-generation sequencing, and fusion genes have been reported to contribute to tumorgenesis[22] . For example, recurrent fusions of R-spondin family members RSPO2 and RSPO3, which occur in 10% of colon tumors, have been reported to be involved in the activation of Wnt signaling pathway[23]. NCOA2, a negative growth regulator repressing Wnt signaling pathway, was reported to be disrupted by recurrent fusion with LACTB2 in colorectal cancer. We believe this method can be a less-invasive and personalized monitoring technique with high sensitivity and specificity for translocation-derived diseases, including some cancers.

This technique has some limitations. Sufficient amounts of gDNA from tissue samples need to be obtained to confirm the intronic breakpoint. Frozen tumor samples may be preferred over formalin-fixed tissues to prevent yield decrease because of fragmentation of DNA samples in the latter tissues. Furthermore, although we demonstrated the detection of the fusion sequence in cfDNA of a gastric SS patient, the sensitivity of RT-PCR using cfDNA obtained from 2 mL plasma was not so high (Ct value, 35.9) because of a small amount of cfDNA. A more advanced method to obtain high-quality or large amounts of cfDNA may be more appropriate for this technique in the future regarding a stable application. Finally, while the location of gene fusion is almost same for each disease, the intronic breakpoint may differ in each patient. Thus, a specific probe and primer sets should be designed for each patient per disease. In this regard, if the amounts of collected plasma RNA or sensitivity of the RT-PCR method is improved, a specific probe and primer sets for plasma RNA samples would be more useful and become a valuable diagnostic tool. Large-scale studies will be necessary to confirm the sensitivity and specificity of this method.

In conclusion, we demonstrated the detection of the *SYT-SSX* fusion sequence in the plasma circulating cfDNA of a rare gastric SS patient. In the future, this method may be useful for translocation-derived diseases such as SS or for other cancers which contain translocations.

**Article Highlights**

***Case characteristics***

A 27-year-old woman presented upper abdominal pain.

***Clinical diagnosis***

Upper abdominal tenderness associated to the gastric tumor.

***Differential diagnosis***

Stomach tumor including cancer or gastrointestinal stromal tumor.

***Laboratory diagnosis***

Blood tests ruled out opportunistic infections and severe anemia.

***Imaging diagnosis***

Upper gastrointestinal endoscopy and ultrasound endoscopy showed a small submucosal tumor less than 20 mm in diameter in the stomach.

***Pathological diagnosis***

Histological examination of the biopsies showed a spindle cell sarcoma compatible with SS. *SYT-SSX2* fusion gene was detected using biopsy samples by CR methods.

***Treatment***

The submucosal tumor was resected by laparosopic and ecdoscopic cooperative surgery.

***Related reports***

Previous cases of SS whose intronic breakpoints were confirmed using tumor samples have been described.

***Term explanation***

*SYT-SSX* fusion gene is SS-specific genetic alternation and detection of SYT-SSX contributes much to the diagnosis of SS.

***Experiences and lessons***

In patients with SS and other translocation-related diseases, detection of fusion genes specific for those diseases is a powerful diagnostic tool and the detection using liquid sample, such as blood, can be a valuable and less invasive monitoring tool as well.

**References**

1 **Herzog CE**. Overview of sarcomas in the adolescent and young adult population. *J Pediatr Hematol Oncol* 2005; **27**: 215-218 [PMID: 15838394 DOI: 10.1097/01.mph.0000163712.39139.b6]

2 **Turc-Carel C**, Dal Cin P, Limon J, Rao U, Li FP, Corson JM, Zimmerman R, Parry DM, Cowan JM, Sandberg AA. Involvement of chromosome X in primary cytogenetic change in human neoplasia: nonrandom translocation in synovial sarcoma. *Proc Natl Acad Sci USA* 1987; **84**: 1981-1985 [PMID: 3031659 DOI: 10.1073/pnas.84.7.1981]

3 **de Leeuw B**, Balemans M, Olde Weghuis D, Geurts van Kessel A. Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas. *Hum Mol Genet* 1995; **4**: 1097-1099 [PMID: 7655467 DOI: 10.1093/hmg/4.6.1097]

4 **Tamborini E**, Agus V, Mezzelani A, Riva C, Sozzi G, Azzarelli A, Pierotti MA, Pilotti S. Identification of a novel spliced variant of the SYT gene expressed in normal tissues and in synovial sarcoma. *Br J Cancer* 2001; **84**: 1087-1094 [PMID: 11308259 DOI: 10.1054/bjoc.2000.1710]

5 **Güre AO**, Wei IJ, Old LJ, Chen YT. The SSX gene family: characterization of 9 complete genes. *Int J Cancer* 2002; **101**: 448-453 [PMID: 12216073 DOI: 10.1002/ijc.10634]

6 **Crew AJ**, Clark J, Fisher C, Gill S, Grimer R, Chand A, Shipley J, Gusterson BA, Cooper CS. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. *EMBO J* 1995; **14**: 2333-2340 [PMID: 7539744]

7 **Otsuka S**, Nishijo K, Nakayama T, Aoyama T, Ishibe T, Shibata KR, Shima Y, Nakamura T, Otsuka T, Toguchida J. A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma. *Cancer Genet Cytogenet* 2006; **167**: 82-88 [PMID: 16682293 DOI: 10.1016/j.cancergencyto.2005.11.012]

8 **Törnkvist M**, Brodin B, Bartolazzi A, Larsson O. A novel type of SYT/SSX fusion: methodological and biological implications. *Mod Pathol* 2002; **15**: 679-685 [PMID: 12065783 DOI: 10.1038/modpathol.3880587]

9 **Torres Rivas HE**, Fernández S, Fresno MF. Primary gastric synovial sarcoma. *Pathology* 2014; **46**: 253-256 [PMID: 24614723 DOI: 10.1097/PAT.0000000000000078]

10 **Michot N**, Robert PE, De Muret A, Marques F, de Calan L, Benchellal Z. Gastric synovial sarcoma: case report and systematic review of literature. *J Gastrointest Cancer* 2014; **45 Suppl 1**: 129-131 [PMID: 24595970 DOI: 10.1007/s12029-014-9591-1]

11 **Chen XQ**, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. *Nat Med* 1996; **2**: 1033-1035 [PMID: 8782463 DOI: 10.1038/nm0996-1033]

12 **Wong IH**, Lo YM, Zhang J, Liew CT, Ng MH, Wong N, Lai PB, Lau WY, Hjelm NM, Johnson PJ. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. *Cancer Res* 1999; **59**: 71-73 [PMID: 9892188]

13 **Le Calvez-Kelm F**, Foll M, Wozniak MB, Delhomme TM, Durand G, Chopard P, Pertesi M, Fabianova E, Adamcakova Z, Holcatova I, Foretova L, Janout V, Vallee MP, Rinaldi S, Brennan P, McKay JD, Byrnes GB, Scelo G. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control. *Oncotarget* 2016; **7**: 78827-78840 [PMID: 27705932 DOI: 10.18632/oncotarget.12386]

14 **Hayashi M**, Chu D, Meyer CF, Llosa NJ, McCarty G, Morris CD, Levin AS, Wolinsky JP, Albert CM, Steppan DA, Park BH, Loeb DM. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. *Cancer* 2016; **122**: 3015-3023 [PMID: 27351911 DOI: 10.1002/cncr.30144]

15 **Sorenson GD**, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. *Cancer Epidemiol Biomarkers Prev* 1994; **3**: 67-71 [PMID: 8118388]

16 **Vasioukhin V**, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. *Br J Haematol* 1994; **86**: 774-779 [PMID: 7918071 DOI: 10.1111/j.1365-2141.1994.tb04828.x]

17 **Schwarzenbach H**, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. *Nat Rev Cancer* 2011; **11**: 426-437 [PMID: 21562580 DOI: doi.org/10.1038/nrc3066]

18 **McDermott U**, Downing JR, Stratton MR. Genomics and the continuum of cancer care. *N Engl J Med* 2011; **364**: 340-350 [PMID: 21268726 DOI: doi.org/10.1056/NEJMra0907178]

19 **Siravegna G**, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. *Genome Biol* 2014; **15**: 449 [PMID: 25222559 DOI: 10.1186/s13059-014-0449-4]

20 **Shoda K**, Ichikawa D, Fujita Y, Masuda K, Hiramoto H, Hamada J, Arita T, Konishi H, Komatsu S, Shiozaki A, Kakihara N, Okamoto K, Taniguchi H, Imoto I, Otsuji E. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer. *Gastric Cancer* 2017; **20**: 126-135 [PMID: 26874951 DOI: 10.1007/s10120-016-0599-z]

21 **Seshagiri S**, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, Chaudhuri S, Guan Y, Janakiraman V, Jaiswal BS, Guillory J, Ha C, Dijkgraaf GJ, Stinson J, Gnad F, Huntley MA, Degenhardt JD, Haverty PM, Bourgon R, Wang W, Koeppen H, Gentleman R, Starr TK, Zhang Z, Largaespada DA, Wu TD, de Sauvage FJ. Recurrent R-spondin fusions in colon cancer. *Nature* 2012; **488**: 660-664 [PMID: 22895193 DOI: 10.1038/nature11282]

22 **Yu J**, Wu WK, Liang Q, Zhang N, He J, Li X, Zhang X, Xu L, Chan MT, Ng SS, Sung JJ. Disruption of NCOA2 by recurrent fusion with LACTB2 in colorectal cancer. *Oncogene* 2016; **35**: 187-195 [PMID: 25823027 DOI: 10.1038/onc.2015.72]

23 **Urakami K**, Shimoda Y, Ohshima K, Nagashima T, Serizawa M, Tanabe T, Saito J, Usui T, Watanabe Y, Naruoka A, Ohnami S, Ohnami S, Mochizuki T, Kusuhara M, Yamaguchi K. Next generation sequencing approach for detecting 491 fusion genes from human cancer. *Biomed Res* 2016; **37**: 51-62 [PMID: 26912140 DOI: 10.2220/biomedres.37.51]

**P-Reviewer:** Vorobjova T **S-Editor:** Gong ZM

**L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

****

A

C

B

**Figure 1 Identification of the *SYT-SSX2* fusion transcript.** A: Structure of the *SYT-SSX2* fusion transcript. Exon 10 of the *SYT* gene and exon 6 of the *SSX2* gene are fused together in this transcript. The sequencing of exon is shown. Forward and reverse primers were designed in exon 10 of the *SYT* gene and exon 6 of the *SSX2* gene, respectively;B: The RT-PCR product, including the *SYT-SSX2* fusion site, was obtained from tumor tissue samples only. This analysis was performed more than three times, and a representative result of an electrophoresis is shown; C: The result of direct sequencing of the PCR product is shown. Exon 10 of the *SYT* gene is fused to exon 6 of the *SSX2* gene.



B

C

A

**Figure 2 Detection of the *SYT-SSX2* fusion sequence.** A: The intronic primer settings in the *SYT* and *SSX2* genes are shown; B: Genomic PCR products were obtained from tumor tissue samples only. This analysis was performed more than two times, and a representative result of an electrophoresis is shown; C: The intronic breakpoint was confirmed by direct sequencing.



A

B

**Figure 3 Intronic breakpoint and structure of the fusion sequence with specific probe and primer sets.** A:The arrowheads indicate the position and sequence of the intronic breakpoint of the *SYT* and *SSX2* genes; B: The structure and sequence of the FAM-labeled probe and primer sets specific to the intronic breakpoint of the *SYT-SSX* fusion sequence.



A

B

**Figure 4 Detection of the fusion gene sequence in cfDNA using specific probe and primer sets.** A: The range of reproducibility of RT-PCR with the specific probe and primer sets was confirmed. Diluted serial tumor gDNA of 1–0.063 ng was used. The dotted line indicates an approximate curve (R² = 0.9742, *P* = 0.0018); B: cfDNA samples of a patient and 10 healthy volunteers were analyzed using RT-PCR. RT-PCR was performed in duplicate, and mean Ct values are indicated. Standard deviation was calculated from duplicate samples.

**Table 1 Overview of primers and probe sequences for all PCR methods**

|  |  |  |
| --- | --- | --- |
| **Primers (5’-3’)**  | **Sequence** | **Product size (bp)** |
| Reverse transcription PCR |  |  |
| SYT-sense  | CCAGCAGAGGCCTTATGGA | 118 |
| SSX2-antisense | GCACAGCTCTTTCCCATCA |  |
| Genomic PCR |  |  |
| SYT1-sense | GTAGTTTGACCGGCTGCAGAA |  |
| SYT2-sense | GGTGGTCTGGTTTGTTCACC |  |
| SYT3-sense | GCAAATGTTTATTGAGCAACCA |  |
| SYT4-sense | GGGAGAAATTAAAAGGGTGGA |  |
| SYT5-sense | CACCTGTGAAACCATCAGCA |  |
| SYT6-sense | TTTTCTTTATGGATTATGCTTTTGG |  |
| SYT7-sense | GCTTACTAGGAGTTTCATTGTAATTG |  |
| SYT8-sense | CAGCCTGATAAACTGTATACC |  |
| SYT9-sense | GATTTGAATGCGTGATCACAAG |  |
| SYT10-sense | GATTGGATTCCAGACATTGTG |  |
| SYT11-sense | GCCACCTTGGAATTTGTTAATG |  |
| SYT12-sense | CTGATGATTGAAGAAACCGAG |  |
| SSX2-1-antisense | ACGGAGAATCAGGGTTCTTTGG |  |
| SSX2-2-antisense | TCAGTCTCCACACTGGCAAC |  |
| SSX2-3-antisense | TCAAGGCAACATCCGACTCC |  |
| SSX2-4-antisense | TGGTTTCCAGGGATAGAATGCT |  |
| Real-time PCR |  |  |
| SYT-specific-sense | CCAGCAACAGTAGTTTACTTTCTATC | 106 |
| SSX2-specific-antisense | AAACATAGGGAGGCGACAAA |  |
| SYT-SSX2-FAM probe-sense | ATA+CAA+T+C+CA+G+CAG1 |  |
| 1+C, +T, +G = LNA base. |  |  |

**Table 2 Results of RT-PCR analysis by the specific probe and primer sets**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Types of DNA** | **Sample** | **Ct value 1** | **Ct value 2** | **Mean** |
| Genomic | Normal tissue | Undetermined | Undetermined | Undetermined |
|  | Tumor tissue | 31.94651 | 31.30283 | 31.62467 |
| β-actin | Tumor tissue | 28.97511 | 30.95062 | 29.96287 |

Undetermined: No Ct detection till 40 cycles.